Loading…
Holding company atop Hanmi Pharmaceutical group, also running early-stage biotech and health-related ventures.
Holding company atop Hanmi Pharmaceutical group, also running early-stage biotech and health-related ventures.
A pure holding company: its income is dividends and brand fees from subsidiaries, so it gets the group's profits only after they are paid out. Hanmi Pharmaceutical is the main operating subsidiary.
Moat: none. Pure holding company; value depends on operating subsidiary Hanmi Pharmaceutical.
Headquarters: Seoul, South Korea · Employees: 489
Size Hanmi Science (008930.KS) is a South Korea Health Care company (Medical Distributors) with a market value of $2.71B, the 108th largest of 495 South Korea companies the cockpit tracks. Shares closed at ₩54,300 on 6 Nov 2026.
Performance Over six months the shares gained 44.0%, against +3.3% for the median peer and -24.5% for the South Korea market (cap-weighted) — 4th highest of 21 in its peer set.
Growth Revenue grew 6.2% over the last twelve months (peer median +5.2%); the operating margin is 4.7% (peer median 3.0%).
Valuation It trades at 2.6× enterprise value to sales against a peer median of 0.5× (most expensive of 21).
Price implies For today's price to make sense, revenue must grow about 24% a year for seven years (Req g). Recent delivered growth is +10%, so the hurdle is +15 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 0.4 points below its cost of capital (5.5% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₩1.43T | ₩1.36T | ₩1.28T | ₩1.25T | ₩1.05T |
| Revenue growth | — | +6% | +3% | +19% | — |
| Gross profit | n/a | ₩272B | ₩233B | ₩227B | ₩102B |
| EBITDA | n/a | ₩66.4B | ₩47.7B | ₩65.7B | ₩33.6B |
| Net income | ₩134B | ₩118B | ₩59.4B | ₩115B | ₩69.2B |
| Free cash flow | n/a | ₩28.7B | ₩73.2B | ₩28.2B | ₩2.32B |
| Capital expenditure | n/a | ₩21.0B | ₩11.7B | ₩8.77B | ₩8.44B |
| Total debt | n/a | ₩215B | ₩227B | ₩222B | ₩202B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Hanmi Science 008930.KS | $2.71B | +44% | +6% | 5% | 2.6× | 24.2% |
| HanmiPharm 128940.KS | $4.36B | +2% | +14% | 16% | 3.5× | 5.0% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 008930.KS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -6.5% | +4.4% | lowest of 21 |
| 6-month return | +44.0% | +3.3% | 4th highest of 21 |
| Distance from 52-week high | -14.9% | -14.3% | 10th lowest of 21 |
| Revenue growth (TTM) | +6.2% | +5.2% | 10th highest of 21 |
| Operating margin | 4.7% | 3.0% | 7th highest of 21 |
| EV / Sales | 2.6× | 0.5× | most expensive of 21 |
| Growth the price implies (Req g, 7 yrs) | 24.2% | -3.7% | most demanding of 17 |
| Growth delivered (Del g) | +9.6% | +4.6% | 4th highest of 17 |
| Hurdle (Req g minus delivered) | +14.5 pp | -11.3 pp | most demanding of 17 |
| ROIC minus cost of capital | -0.4 pp | +1.6 pp | 5th lowest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Hanmi Science 008930.KS | South Korea | $2.71B | +44% | +6% | 5% | 2.6× | 24.2% | +9.6% |
| Alfresa 2784.T | Japan | $2.79B | -3% | +5% | 1% | 0.1× | -9.1% | +3.5% |
| Asker Healthcare ASKER.ST | Sweden | $2.98B | -5% | +12% | 7% | 1.6× | 1.2% | +12.7% |
| COSMOS Pharmaceutical 3349.T | Japan | $3.20B | +5% | +9% | 4% | 0.5× | n/a | n/a |
| Suzuken 9987.T | Japan | $2.29B | -9% | +5% | 1% | 0.1× | -11.9% | +3.2% |
| MEDIPAL 7459.T | Japan | $3.67B | +14% | +4% | 1% | 0.1× | -7.4% | +3.5% |
| Amplifon AMP.MI | Italy | $3.72B | +13% | 0% | 9% | 1.8× | 9.5% | +9.8% |
| Jointown Pharmaceutical 600998.SS | China | $3.96B | +1% | +9% | 2% | 0.4× | 0.1% | +7.8% |
| Redcare Pharmacy RDC.DE | Germany | $1.63B | +52% | +19% | 0% | 0.5× | n/a | n/a |
| Toho 8129.T | Japan | $1.60B | -14% | +4% | 1% | 0.1× | -7.4% | +5.1% |
| Galenica GALE.SW | Switzerland | $5.46B | +8% | +6% | 5% | 1.3× | 6.9% | +3.5% |
| Ship Healthcare 3360.T | Japan | $1.34B | +4% | +7% | 3% | 0.2× | -14.7% | +7.6% |
| Shanghai C and D INNOSTIC Medical Technology 301584.SZ | China | $1.20B | -28% | +8% | 3% | 0.6× | -1.3% | +17.9% |
| DKSH DKSH.SW | Switzerland | $6.10B | +29% | -1% | 3% | 0.5× | -1.4% | +0.6% |
| Shinva Medical Instrument 600587.SS | China | $1.16B | -7% | +6% | 5% | 0.7× | -5.9% | +1.2% |
| AS ONE 7476.T | Japan | $1.08B | +15% | +10% | 12% | 1.3× | -1.0% | +6.3% |
| Sinopharm 1099.HK | Hong Kong | $6.83B | -4% | +3% | 3% | 0.3× | -8.1% | +4.0% |
| Nanjing Pharmaceutical 600713.SS | China | $1.03B | +1% | +3% | 2% | 0.3× | n/a | n/a |
| DocMorris DOCM.SW | Switzerland | $1.02B | +136% | +11% | -8% | 0.9× | n/a | n/a |
| Arjo ARJO-B.ST | Sweden | $1.02B | +48% | 0% | 8% | 1.3× | -1.3% | +3.9% |
| Guangxi LiuYao 603368.SS | China | $994M | +2% | +2% | 5% | 0.4× | -9.5% | +6.0% |